N-(5-aminopyridin-2-yl)benzamide | 69634-20-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-aminopyridin-2-yl)benzamide
• 英文别名: 5-Amino-2-benzoylamino-pyridin；N-(5-amino-[2]pyridyl)-benzamide；N-(5-Amino-[2]pyridyl)-benzamid
• CAS: 69634-20-4
• 化学式: C₁₂H₁₁N₃O
• mdl: MFCD08898857
• 分子量: 213.239
• InChiKey: PMCJOARICUKEBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(5-aminopyridin-2-yl)benzamide 、 1-chloro-5H-benzo[c][1,8]naphthyridin-6-one 在 palladium diacetate 、 sodium t-butanolate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-(5-(6-oxo-5,6-dihydrobenzo[c][1,8]naphthyridin-1-ylamino)pyridin-2-yl)benzamide
  参考文献：
  名称：

  SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors

  摘要：

  Several potent Aurora kinase inhibitors derived from 5H-benzo[c][1,8]naphthyridin-6-one scaffold were identified. A crystal structure of Aurora kinase A in complex with an initial hit revealed a binding mode of the inhibitor within the ATP binding site and provided insight for structure-guided compound optimization. Subsequent SAR campaign provided a potent and selective pan Aurora inhibitor, which demonstrated potent target modulation and antiproliferative effects in the pancreatic cell line, MIAPaCa-2. Furthermore, this compound inhibited phosphorylation of histone H3 (pHH3) in mouse bone morrow upon oral administration, which is consistent with inhibition of Aurora kinase B activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.008
• 作为产物：
  描述：

  N-(5-nitropyridin-2-yl)benzamide 在 钯 、 溶剂黄146 作用下， 生成 N-(5-aminopyridin-2-yl)benzamide
  参考文献：
  名称：

  Heterocyclic Studies. VII. The Preparation and Reactions of 2-Amino-5-hydroxypyridines; the Formation of an Azaquinone¹

  摘要：

  DOI：

  10.1021/ja01531a047

文献信息

• COMPOUNDS EFFECTING GLUCOKINASE
  申请人：BOYD Scott

  公开号：US20090227592A1

  公开（公告）日：2009-09-10

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用式（I）化合物或其盐、溶剂化物或前药，在制备用于治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一种新的式（I）化合物群以及制备式（I）化合物的方法。其中，R1、R2、R3、n和m如规范中所述。
• Compounds Effecting Glucokinase
  申请人：Boyd Scott

  公开号：US20080207636A1

  公开（公告）日：2008-08-28

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用化合物式(I)或其盐、溶剂化物或前药，其中R1、R2、R3、n和m如规范所述，在制备治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一类新的化合物式(I)和制备化合物式(I)的方法。
• CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0904262B1

  公开（公告）日：2004-04-21
• Compounds effecting glucokinase
  申请人：AstraZeneca AB

  公开号：EP1568367B1

  公开（公告）日：2007-04-18
• US7390908B2
  申请人：——

  公开号：US7390908B2

  公开（公告）日：2008-06-24